Akari Therapeutics, Plc
AKTX
$0.34
$0.00-0.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -19.45% | -9.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -28.70% | -11.52% | |||
| Operating Income | 28.70% | 11.52% | |||
| Income Before Tax | -295.15% | 48.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -237.73% | 48.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -237.73% | 48.85% | |||
| EBIT | 28.70% | 11.52% | |||
| EBITDA | 28.73% | 11.53% | |||
| EPS Basic | -225.42% | 55.64% | |||
| Normalized Basic EPS | 58.08% | 28.80% | |||
| EPS Diluted | -225.42% | 55.64% | |||
| Normalized Diluted EPS | 58.08% | 28.80% | |||
| Average Basic Shares Outstanding | 3.78% | 15.31% | |||
| Average Diluted Shares Outstanding | 3.82% | 15.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||